Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Basit Öğe Kaydı
dc.contributor.authorBilgin, Burak
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorYucel, Sebnem
dc.contributor.authorCelik, Emir
dc.contributor.authorOzyukseler, Deniz Tataroglu
dc.contributor.authorAyhan, Murat
dc.contributor.authorBasoglu, Tugba
dc.date.accessioned2024-04-24T16:01:54Z
dc.date.available2024-04-24T16:01:54Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that investigate the efficacy and safety of the new generation TKIs in real-world patients. Thus, we aimed to compare the efficacy and safety of the afatinib, an irreversible inhibitor of ErbB family receptor, and first-generation TKIs in real-world patients. Materials and methods We included advanced nonsmall cell lung cancer (NSCLC) patients who had EGFR exon 19del mutation and treated with afatinib or first-generation TKIs as upfront treatment between 2016 and 2020. All patient's information was collected retrospectively. The study cohort was divided as afatinib arm and erlotinib/gefitinib arm. Results A total of 283 patients at the 24 oncology centers were included. The 89 and 193 of whom were treated with afatinib and erlotinib/gefitinib, respectively. After 12.9 months (mo) of follow-up, the median PFS was statistically longer in the afatinib arm than erlotinib/gefitinib arm (19.3 mo vs. 11.9 mo, p: 0.046) and the survival advantage was more profound in younger patients (< 65 years). The 24-mo overall survival rate was 76.1% and 49.5% in the afatinib arm and erlotinib/gefitinib arm, respectively. Although all-grade adverse event (AE) rates were similar between the two arms, grade 3-4 AE rates were higher in the afatinib arm (30.7% vs. 15.2%; p: 0.004). Discussion In our real-world study, afatinib has superior survival outcomes despite worse toxicity profile as inconsistent with clinical study results and it is the good upfront treatment option for younger patients and elderly patients who have good performance status.en_US
dc.identifier.doi10.1007/s00432-020-03501-6
dc.identifier.endpage2152en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue7en_US
dc.identifier.pmid33433657
dc.identifier.scopus2-s2.0-85099197058
dc.identifier.scopusqualityQ3
dc.identifier.startpage2145en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-020-03501-6
dc.identifier.urihttps://hdl.handle.net/11468/14473
dc.identifier.volume147en_US
dc.identifier.wosWOS:000608139100004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Cancer Research and Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAfatiniben_US
dc.subjectErlotiniben_US
dc.subjectExon 19 Delen_US
dc.subjectGefitiniben_US
dc.subjectNsclcen_US
dc.titleReal-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyen_US
dc.titleReal-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu